SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp gold selloff pushed the ETF to a 52-week low, with traders citing inflation concerns and expectations of higher interest rates as pressure on precious metals. The community is split between bearish calls for further declines and buyers viewing the pullback as a potential bottom, while many question why gold has not acted as a safe haven during broader market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductors are under heavy selling pressure as traders question whether enormous AI infrastructure spending will generate sufficient returns, with weak Intel guidance and Amazons elevated capex adding to the sectors strain. The community is split between warnings of an AI-trade unwind and dip buyers who see ongoing chip demand and the selloff as an opportunity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, powered by Eylea HD sales and Sanofi collaboration revenue tied to Dupixent, are driving the sharp move. Traders are broadly positive about the earnings beat and breakout, while discussing whether newer medicines and pipeline programs can sustain growth.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CTO Realty Growth Q3 2026 Earnings Call Transcript

CTO Realty Growth (NYSE:CTO) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

CTO Realty (CTO) Q3 FFO Miss Estimates

CTO Realty (CTO) delivered FFO and revenue surprises of -1.79% and +1.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

NETSTREIT (NTST) Matches Q3 FFO Estimates

NETSTREIT (NTST) delivered FFO and revenue surprises of 0.00% and +5.40%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

What Makes CTO Realty (CTO) a New Buy Stock

CTO Realty (CTO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CTO Realty (CTO) Is a Great Choice for 'Trend' Investors, Here's Why  

CTO Realty (CTO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CTO Realty (CTO) Moves to Strong Buy: Rationale Behind the Upgrade

CTO Realty (CTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for August 6th

ASMIY, NTRS, TXN, CTO and ING have been added to the Zacks Rank #1 (Strong Buy) List on August 6th, 2026.

Best Income Stocks to Buy for August 6th

CTO, ING and TXN made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 6th, 2026.

Here's Why Momentum in CTO Realty (CTO) Should Keep going

CTO Realty (CTO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

CTO Realty (CTO) Tops Q2 FFO and Revenue Estimates

CTO Realty (CTO) delivered FFO and revenue surprises of +1.85% and +1.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of -$0.19 down -733.33% YoY
• Reported revenue of $46.91M up 24.23% YoY
• CTO Realty Growth raised 2026 Core FFO per diluted share guidance to $2.11 to $2.14 and revised AFFO per diluted share guidance to $2.22 to $2.25.

CTO Realty Growth posted a 3Q 2026 net loss, occupancy decreased 180 basis points year over year with Zona Rosa 67% leased, and revised 2026 G&A guidance to $21M from $20M.

CTO Realty Growth's Core FFO per diluted share was up 10% year over year; shopping center NOI increased 3.8%, leases had a 7% cash rent spread, and investments totaled $472.3M at 9.4% weighted average yield.

CTO Realty Growth, Inc. operates as a real estate company. The firm owns and manages commercial real estate properties. It operates through the following segments: Income Properties, Management Services, Commercial Loans and Investments, and Real Estate Operations. The company was founded in 1910 and is headquartered in Winter Park, FL.

CTO Realty Growth Inc - Ordinary Shares- New

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$19.71
Prev Close	$19.59
Open	$19.76
Dividend Yield	8.26%
50-Day Moving Average	$20.70
Beta	0.36
Avg. Volume	416,647.26
PE Ratio	17.13

52-Week High	$22.71
52-Week Low	$16.50
Market Capitalization	$759.31M
EPS (Annual)	$0.0799
Price to Book	1.11
Revenue Per Employee	$3.56M

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTO Fundamentals